GoodRx Holdings, Inc. (GDRX), a platform for medication savings in the U.S., Monday said it has partnered with Novo Nordisk to offer diabetes medicine Ozempic and obesity treatment Wegovy for $499 per month to self-paying customers.
"By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them," said Wendy Barnes, President and Chief Executive Officer of GoodRx.
"This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic self-pay offer for type 2 diabetes patients at an unprecedented price," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.